Floatz logo

Vibisone

Glucose Intolerance

The University of Texas Health Science Center, HoustonSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Glucose Intolerance cohort.

Asset / SponsorPhaseRating
DULAGLUTIDE
University of Pennsylvania
Phase 4BBB
Dexmedetomidine
Pontificia Universidad Catolica de Chile
Phase 4BB
NEPENTHE
Washington University School of Medicine
Phase 4BB
FENTANYL
Pontificia Universidad Catolica de Chile
Phase 4BB
CANDESARTAN
Fundación Cardiovascular de Colombia
Phase 4BB

View all 15 →

Same molecule, other indications

Vibisone is also rated in:

myocardial infarctionDormant
BB
Indicative · Phase 3
66 / 100
View asset →
obesity disorderDormant
BB
Indicative · Phase 4
65 / 100
View asset →
cerebral infarctionDormant
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →